Neuronetics Posts Mixed Q1 2026 Results with Clinic Growth and Cash Burn

Event summary

  • Q1 2026 revenue of $34.5M, up 8% YoY, driven by 15% growth in U.S. clinic revenue.
  • Shipped 34 NeuroStar systems in the U.S., a 10% increase YoY.
  • Net cash used in operations reduced by $7.6M YoY to $9.4M.
  • Optum/UHC/UBH expanded TMS clinical policy to include nurse practitioners.
  • Full-year 2026 revenue guidance set at $160M–$166M.

The big picture

Neuronetics' Q1 2026 results highlight a strategic focus on clinic expansion and operational efficiency, despite mixed revenue trends. The company's ability to leverage regulatory changes, such as the Optum/UHC/UBH policy expansion, will be critical in driving long-term growth in the competitive neurohealth therapy market. With full-year revenue guidance set at $160M–$166M, the company's execution on cost management and cash flow improvement will be key to realizing its strategic vision.

What we're watching

Revenue Diversification
Whether Neuronetics can sustain clinic revenue growth amid declining international sales.
Cash Flow Management
The pace at which Neuronetics can reduce cash burn while investing in growth.
Regulatory Impact
How the expanded TMS clinical policy will affect patient access and clinic utilization.